Reported Saturday, Pfizer's Berobenatide Achieves 15.9% Weight Loss At 32 Weeks With No Plateau In VESPER-1 As Monthly GLP-1 Phase 3 Program Advances

Pfizer

Pfizer

PFE

0.00
  • Results from multiple Phase 2b dose finding studies for berobenatide (PF'3944) highlight a potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, and support the planned Phase 3 low, medium and high dosing strategy
  • VESPER-1 achieved a non-placebo-adjusted weight loss of almost 16% with no plateau observed at 32 weeks on 2.4 mg weekly berobenatide
  • Pfizer plans to advance 10 Phase 3 studies for berobenatide in 2026 for chronic weight management and obesity-related comorbidities including knee osteoarthritis and obstructive sleep apnea, as part of a broader program of 20+ obesity trials
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.